Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06374459 · ClinicalTrials.gov registry record · Phase 1
Zunsemetinib in Combination With Capecitabine in Patients With Hormone Receptor-Positive and HER2-Negative Metastatic Breast Cancer With Bone Metastasis
A Phase 1 study of Hormone Receptor Positive HER-2 Negative Metastatic Breast Cancer, sponsored by Washington University School of Medicine.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 152
- Enrollment target
- 3
- Study locations
NCT06374459 is a Phase 1 study of Hormone Receptor Positive HER-2 Negative Metastatic Breast Cancer that is actively recruiting participants, run by Washington University School of Medicine. The registered enrollment target is 152 participants. The trial reports 3 study locations across 3 states.
The verdict
NCT06374459, a Phase 1 study of Hormone Receptor Positive HER-2 Negative Metastatic Breast Cancer, is actively recruiting participants, sponsored by Washington University School of Medicine.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 152 participants
- Enrollment target
- 3
- Study locations
Study Summary
This is a phase Ib/II study evaluating the safety and efficacy of zunsemetinib (ATI-450) with capecitabine in patients with hormone receptor-positive and HER2-negative (HR+/HER2-) metastatic breast cancer (MBC).
Conditions Studied
Interventions
- DRUG Capecitabine
- DRUG Zumsemetinib
- DRUG Zoledronic acid
- DRUG Denosumab
Study Locations (3)
Kansas
- The University of Kansas Cancer Center - Westwood
Minnesota
- Mayo Clinic - Rochester
Missouri
- Washington University School of Medicine - St Louis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 152 participants |
| Start Date | 2025-01-30 |
| Est. Completion | 2032-05-31 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06374459
The ClinicalTrials.gov registry entry for NCT06374459 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 152 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Washington University School of Medicine, which has 1,502 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Hormone Receptor Positive HER-2 Negative Metastatic Breast Cancer appearing as the primary indexed condition, and to 4 interventions - of which Capecitabine is the first listed.
NCT06374459 reports 3 study locations spanning 3 distinct geographic areas - top geographies include Kansas, Minnesota, Missouri.
Frequently Asked Questions
What is clinical trial NCT06374459 about?
NCT06374459 is a clinical study titled "Zunsemetinib in Combination With Capecitabine in Patients With Hormone Receptor-Positive and HER2-Negative Metastatic Breast Cancer With Bone Metastasis". This is a phase Ib/II study evaluating the safety and efficacy of zunsemetinib (ATI-450) with capecitabine in patients with hormone receptor-positive and HER2-negative (HR+/HER2-) metastatic breast cancer (MBC).
What is the current status of trial NCT06374459?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 152 participants. The study started on 2025-01-30. Estimated completion is 2032-05-31.
What conditions does trial NCT06374459 study?
This clinical trial studies the following conditions: Hormone Receptor Positive HER-2 Negative Metastatic Breast Cancer.
What interventions are being tested in trial NCT06374459?
The interventions under investigation include: Capecitabine (DRUG), Zumsemetinib (DRUG), Zoledronic acid (DRUG), Denosumab (DRUG).
Who is sponsoring clinical trial NCT06374459?
This trial is sponsored by Washington University School of Medicine, which has 1,502 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06374459 being conducted?
This trial has 3 study locations across Kansas, Minnesota, Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.